Global PARP Inhibitor Market

The global PARP inhibitor market accounted for USD 5.82 billion in 2023 and is expected to reach at USD 14.61 billion by 2034 with a CAGR of 8.73% during the forecast period 2024-2034. The expansion of the market will be fueled by factors such as rising cancer incidence, advances in precision medicine, R&D investments, and strategic alliances.

PARP inhibitors are a component of the paradigm shift toward precision medicine, in which patients receive customized care based on their genetic composition. Growing knowledge of the importance of DNA repair pathways, especially in malignancies with BRCA mutations, is fueled by advances in genomic profiling and molecular diagnostics and is pushing the use of PARP inhibitors. For instance, AstraZeneca Lynparza (olaparib) is approved by the FDA in August 2023 as a first-line maintenance treatment for advanced pancreatic cancer with a germline BRCA mutation.

By drug type, the olaparib segment accounted for the highest revenue-grossing segment in the global PARP inhibitor market in 2023 owing to the high efficacy, established market presence, and broad indications across multiple cancer types, particularly ovarian and breast cancer. For instance, Merck & Co. published good results in December 2023 from the Phase III trial (KEYNOTE-900) for the treatment of first-line advanced non-small cell lung cancer (NSCLC) with BRCA mutations when dostarlimab (anti-PD-1 therapy) was paired with the PARP inhibitor olaparib (Lynparza). Additionally, the niraparib and rucaparib segment is predicted to grow at the fastest CAGR during the forecast period owing to their expanding indications, increasing adoption in prostate cancer, and ongoing clinical trials exploring their efficacy in various cancer types.

By indication, the ovarian cancer segment accounted for the highest revenue-grossing segment in the global PARP inhibitor market in 2023 owing to the high prevalence of ovarian cancer, early approvals of PARP inhibitors for this indication, and the significant unmet medical need in the treatment of advanced ovarian cancer. For instance, in February 2024, GlaxoSmithKline reported that zejula (niraparib) and pembrolizumab show encouraging results in a Phase Ib trial for the treatment of platinum-resistant ovarian cancer. Additionally, the prostate cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of PARP inhibitors' efficacy in treating metastatic castration-resistant prostate cancer (mCRPC), expanding research and development efforts, and rising prevalence of prostate cancer worldwide.

By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global PARP inhibitor market in 2023 owing to the high demand for specialized cancer care, the requirement for close monitoring and administration by healthcare professionals, and the availability of comprehensive oncology services in hospital settings. For instance, in October 2023, AbbVie began a Phase I clinical trial for ABBVIE-3905, a PARP inhibitor that targets deficits in homologous recombination repair (HRR) in a variety of solid cancers. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of telemedicine and online healthcare services, convenience for patients in accessing medications, and expanding digital infrastructure facilitating online pharmaceutical transactions.

North American region is anticipated to have the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, early adoption of innovative therapies, significant investment in research and development, and high prevalence of cancer-driving demand for PARP inhibitors. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness about cancer treatment options, improved healthcare infrastructure, rising prevalence of cancer, and growing adoption of targeted therapies in the region. For instance, the FDA approved talazoparib (Talzenna) and enzalutamide (Xtandi) together in 2023 as a first treatment for certain patients with metastatic castration-resistant prostate cancer.

This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Drug Type, Indication, and Distribution Channel
• Market Forecast for 5 Regions and 17+ Countries
• North America (U.S. and Canada)
• Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
• MEA (South Africa, GCC, Rest of MEA)
• Exhaustive Company Profiles of the Top 10+ Major Market Players

Segmentation: PARP Inhibitor Market Report 2023 - 2034

PARP Inhibitor Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)

• Olaparib
• Niraparib
• Rucaparib
• Talazoparib

PARP Inhibitor Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)

• Ovarian Cancer
• Breast Cancer
• Prostate Cancer
• Pancreatic Cancer

PARP Inhibitor Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

PARP Inhibitor Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA